LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS)

Recruiting Phase 3 Interventional Study
Septic Shock
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
44 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The objectives of this study are to evaluate the effect of continuous intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours ) up to a 15% decrease in Heart Rate (HR) on microcirculatory vascular reactivity vs. usual tachycardia management and evaluate the hemodynamic effects of Landiolol vs. usual management in patients with septic shock.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Sinus tachycardia not compensatory, if the doctor considers that the heart rate acceleration should be treated. * The study will be carried out in * reanimated and stabilized septic shock defined as: * Septic shock is tachycardic (HR\>100/min) patients with sepsis (suspecte…
Contacts

Hafid AIT-OUFELLA, Professor

01 49 28 23 15

hafid.aitoufella@aphp.fr

CONTACT